A randomized open study to assess the efficacy and tolerability of dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia
- 1 February 2007
- journal article
- research article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 12 (2), 251-259
- https://doi.org/10.1111/j.1365-3156.2006.01786.x
Abstract
The definitive version is available at www3.interscience.wiley.comOBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in CambodiaKeywords
This publication has 15 references indexed in Scilit:
- A Randomized, Controlled Study of a Simple, Once-Daily Regimen of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated, Multidrug-Resistant Falciparum MalariaClinical Infectious Diseases, 2005
- Cambodia's fight against malariaThe Lancet, 2005
- Randomized, Controlled Dose‐Optimization Studies of Dihydroartemisinin‐Piperaquine for the Treatment of Uncomplicated Multidrug‐Resistant Falciparum Malaria in ThailandThe Journal of Infectious Diseases, 2004
- Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin®) in Cambodian children and adults with malariaBritish Journal of Clinical Pharmacology, 2003
- Efficacy and Safety of Dihydroartemisinin‐Piperaquine (Artekin) in Cambodian Children and Adults with Uncomplicated Falciparum MalariaClinical Infectious Diseases, 2002
- Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand.The American Journal of Tropical Medicine and Hygiene, 2002
- Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective studyThe Lancet, 2000
- Efficacy and tolerability of a low-dose mefloquine-sulfadoxine-pyrimethamine combination compared with chloroquine in the treatment of acute malaria infection in a population with multiple drug-resistant Plasmodium falciparum.The American Journal of Tropical Medicine and Hygiene, 1999
- Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand.The American Journal of Tropical Medicine and Hygiene, 1999
- Interval estimation for the difference between independent proportions: comparison of eleven methodsStatistics in Medicine, 1998